Talk:SUIT-016

From Bioblast
Jump to: navigation, search
SUIT states: 1-2OctM(LP);3GMOct;4GMSOct;5-7S(PLEc);8ROX
Step Respiratory state Pathway control Pathway to Q Comment
1OctM OctM(L) F CETF
2D OctM(P) F CETF OXPHOS-coupling efficiency in state F.
3G GMOct(P) FN FAO&CI F/N ratio or (N-F)/N flux control factor of OXPHOS capacity.
4S GMSOct(P) FNS FAO&CI&II Additive effect of the NS pathway combination, compared to the sum of N+S pathway fluxes measured separately, in the OXPHOS state and the presence of F.
5Rot S(P) S CII The P/E ratio is not obtained in the FNS state, with preference given to the next steps for OXPHOS-coupling efficiency. A succinate concentration of >10 mM may be required for saturating SP capacity.
6Omy S(L) S CII OXPHOS-coupling efficiency in state S, comparable to state F.
7U S(E) S CII The complete ET capacity in state S may not be obtained after oligomycin. If apparent P/E>1.0, this is corrected to 1.0.
7c S(E) S CII If cytochrome c control factors = 0.0, the cytochrome c test conducted at this very late ET-pathway state provides an additional indication of stability of the mt-preparation during the experimental assay. Application of the cytochrome c test earlier in the protocol (SUIT-011: 1GM;2D;2c;3S; ..) is preferable, if cytochrome c control factors > 0.0 may be observed occasionally or regulary. If such cytochrome c effects are not exclusion criteria, then OXPHOS states with all substrate combinations can be compared in the presence of cytochrome c.
8Ama ROX ROX ROX may be lower in substrate states earlier in the SUIT protocol. Therefore, this ROX measurement is frequently taken as a methodological control rather than as the basis of ROX correction of mitochondrial respiration (mt).